Generation of a chimeric hepatitis C replicon encoding a genotype-6a NS3 protease and assessment of boceprevir (SCH503034) sensitivity and drug-associated mutations

Antiviral Therapy

Volumn 20, Issue 3, 2015, Pages 271-280

  Aloia, Amanda L ^a   Eyre, Nicholas S ^a   Black, Stuart ^b   Bent, Stephen J ^c   Gaeguta, Adriana ^a   Guo, Zhuyan ^b   Narayana, Sumudu K ^a   Chase, Robert ^b   Locarnini, Stephen ^d   Carr, Jill M ^e   Howe, John A ^b   Beard, Michael R ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^e FLINDERS UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; PROLINE; VIRUS PROTEIN;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; EC50; HEPATITIS C VIRUS GENOTYPE 6; NEXT GENERATION SEQUENCING; NONHUMAN; PRIORITY JOURNAL; REPLICON; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS MUTATION; VIRUS REPLICATION; ANALOGS AND DERIVATIVES; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; GENETIC RECOMBINATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMAN; MICROBIAL SENSITIVITY TEST; MUTATION; TUMOR CELL LINE; VIROLOGY;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; PROLINE; RECOMBINATION, GENETIC; REPLICON; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84937542202     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2850     Document Type: Article

References (32)

1. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3:47-52.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
3. Hnatyszyn HJ. Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes. Antivir Ther 2005; 10:1-11.
4. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 Suppl 2:61-80.
5. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50:1013-1020.
6. Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem 2004; 279:17508-17514.
7. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110-113.
8. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-796.
9. Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006; 103:7408-7413.
10. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A 2006; 103:2310-2315.
11. Saeed M, Gondeau C, Hmwe S, et al. Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology 2013; 144:56-58 e7.
12. Peng B, Yu M, Xu S, et al. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 2013; 144:59-61 e6.
13. Yu M, Peng B, Chan K, et al. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother 2014; 58:2638-2646.
14. Imhof I, Simmonds P. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. J Virol 2010; 84:4597-4610.
15. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141:1067-1079.
16. Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J. Differential sensitivity of 5?UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 2014; 146:812-821.e4.
17. Ikeda M, Yi M, Li K, Lemon SM. Selectable subgenomic and genome-length dicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002; 76:2997-3006.
18. Eyre NS, Phillips RJ, Bowden S, et al. Hepatitis B virus and hepatitis C virus interaction in Huh-7 cells. J Hepatol 2009; 51:446-457.
19. Lindgreen S. AdapterRemoval: easy cleaning of next-generation sequencing reads. BMC Res Notes 2012; 5:337.
20. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9:357-359.
21. Wilm A, Aw PP, Bertrand D, et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets. Nucleic Acids Res 2012; 40:11189-11201.
22. Prongay AJ, Guo Z, Yao N, et al. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino- 1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization. J Med Chem 2007; 50:2310-2318.
23. Zhou Z, Wang N, Woodson SE, et al. Antiviral activities of ISG20 in positive-strand RNA virus infections. Virology 2011; 409:175-188.
24. Krieger N, Lohmann V, Bartenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations. J Virol 2001; 75:4614-4624.
25. Tong X, Bogen S, Chase R, et al. Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Res 2008; 77:177-185.
26. Binder J, Tetangco S, Weinshank M, et al. Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors. Antiviral Res 2011; 91:102-111.
27. Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006; 70:28-38.
28. Flint M, Mullen S, Deatly AM, et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrob Agents Chemother 2009; 53:401-411.
29. Susser S, Welsch C, Wang Y, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009; 50:1709-1718.
30. Wu S, Kanda T, Nakamoto S, Imazeki F, Yokosuka O. Hepatitis C virus protease inhibitor-resistance mutations: Our experience and review. World J Gastroenterol 2013; 19:8940-8948.
31. Lenz O, Verbinnen T, Lin TI, et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother 2010; 54:1878-1887.
32. Cento V, Mirabelli C, Salpini R, et al. HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors. PLoS ONE 2012; 7:e39652.